HTML
With plasma genotyping, also known as liquid biopsy, you can offer a noninvasive method that evaluates tumor-derived cell-free DNA in a patient's blood. In the case of EGFR mutations associated with advanced NSCLC, liquid biopsies using ddPCR have shown high specificity and sensitivity, a predictive value of 100%, and better turnaround times than traditional biopsies in identifying mutations that may qualify patients for specific tyrosine-kinase inhibitors. Watch the video to see how an oncologist uses genotyping information in deciding on a treatment plan.